At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top San Francisco based CFO’ operating in the Therapeutics space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Shaun Holt
CFO of Berkeley Lights
Shaun joined Berkeley Lights in November 2015 and was appointed Chief Financial Officer in March 2016. Prior to becoming CFO, Shaun was Vice President of Finance. Prior to joining Berkeley Lights, Shaun spent 7 ½ years at Illumina, Inc. heading up various aspects of their Finance organization. His roles included Sr. Director, Global Head of R&D and Business Unit Finance, EMEA Head of Finance, Accounting and Facilities, and Commercial FP&A. He earned a B.S. in Finance from California State University, Stanislaus.
Follow Shaun Holt:
About Berkeley Lights: Berkeley Lights is a provider of research and development services using micro-droplet technology that change the biological processes.
Georgia Erbez
Chief Financial Officer of Harpoon Therapeutics
Georgia Erbez currently works as the Chief Financial Officer for Harpoon Therapeutics. She previously worked at Artelo Biosciences, Inc. as the Member Board Of Directors.
Follow Georgia Erbez:
About Harpoon Therapeutics: Harpoon Therapeutics is a clinical-stage immunotherapy company developing novel T cell engagers (TriTACs) for the treatment of cancer.
Bryan Giraudo
Chief Financial Officer & COO of Gossamer Bio
Mr. Giraudo is the Chief Financial Officer of Gossamer Bio. Previously, he was Senior Managing Director at LEERINK Partners, where he was responsible for LEERINK’s Western North America and Asia life sciences investment banking practice. Prior to joining LEERINK Partners in 2009, Bryan was a Managing Director in Merrill Lynch’s Global Healthcare Investment Banking Group. Bryan received his B.A. from Georgetown University.
Follow Bryan Giraudo:
About Gossamer Bio: Gossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.
McDavid Stilwell
Chief Financial Officer of Coherus Biosciences
McDavid Stilwell is the Chief Financial Officer at Coherus BioSciences.
Follow McDavid Stilwell:
About Coherus Biosciences: Coherus Biosciences develops, manufactures, and commercializes biologic therapeutics for oncology and inflammatory diseases.
Scott Gorton
CFO of Apton Biosystems
Follow Scott Gorton:
About Apton Biosystems, Cloudleaf, Precursor Energetics: Apton Biosystems develops a high-throughput and low-cost sequencing platform that revolutionizes the availability of genetic analysis.
John Borgeson
Chief Financial Officer of ALX Oncology
John Borgeson is our Chief Financial Officer and has served in this position since June 2014. Borgeson brings over 25 years of pharmaceutical industry experience in finance, strategy and operations on a global scale. Previously Borgeson was a Vice President of Finance at Pfizer and a member of Pfizer’s Global Financial Leadership Team. Borgeson’s roles at Pfizer included CFO for Pfizer’s biotherapeutics division and corporate tax executive with responsibility for US and Europe. Under Borgeson’s leadership, Pfizer completed a transformational restructuring of the global tax group that was replicated by other Fortune 50 companies. Borgeson has more recently led finance for a variety of private biotech companies, including Labrys Biologics, which was acquired by Teva Pharmaceuticals for $825 million. He was also CFO of venBio, a venture capital firm with a strong track record in biotechnology investing. Borgeson started his career as an auditor with Ernst & Young and is a certified public accountant. He has an M.B.A. from R.I.T. and an undergraduate degree from the School of Management at the University at Buffalo (S.U.N.Y.).
Follow John Borgeson:
About ALX Oncology, Kodiak Sciences: ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Anthony M. Rimac
Chief Financial Officer of Cognoa
Follow Anthony M. Rimac:
About Cognoa: Cognoa is a behavioral health company focused on improving the lives and outcomes of children and families living with behavioral conditions
Anurag Goel
CFO, Board Of Directors & Investor of Celltheon
Anurag Goel is the CFO/Business Development/Board Of Directors at Celltheon.
Follow Anurag Goel:
About Afferent Technologies, Celltheon: Celltheon is a cell line development and expression technologies company.
Steve Krognes
CFO of Denali Therapeutics
Mr. Steve Krognes serves as Senior Vice President, Regional Head of Finance and IT and Chief Financial Officer of Pharma North America at Genentech, Inc. Mr. Krognes joined Roche in January 2004 as global head of Mergers and Acquisitions. He served as Head of Corporate Finance-Corporate Development of Roche Holding AG. In this role, he led Roche’s internal Mergers and Acquisitions group and was responsible for all Roche transactions worldwide. Prior to joining Roche Holding AG, Mr. Krognes worked as a venture capitalist in Scandinavia, as a mergers and acquisitions investment banker with Goldman Sachs and Danske Bank, and as a management consultant with McKinsey & Co. He has been a Director of California Healthcare Institute since August 2010. He is a second lieutenant in the Royal Norwegian Air Force. Mr. Krognes holds a Master’s in Business Administration from the Harvard Business School and a Bachelor’s in Economics from the Wharton School at the University of Pennsylvania.
Follow Steve Krognes:
About California Healthcare Institute, Denali Therapeutics: Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
Paul A. Stone
Chief Financial Officer & General Counsel of IDEAYA Biosciences
Stone Paul A. joined IDEAYA Biosciences as Chief Financial Officer, General Counsel in 2018.Paul A. Stone, J.D. joined 5AM Ventures in July 2009 as General Counsel and Chief Operating Officer. In addition to his legal and operational responsibilities, he serves as a Board Observer at Kinestral, Rennovia and Wildcat. Mr. Stone has held managerial and operating roles at several private and public biopharmaceutical companies. Most recently he was General Counsel and Senior VP Intellectual Property at Ethos Pharmaceuticals. Previously he was Senior VP, General Counsel, and Chief Patent Counsel at Ilypsa (acquired by Amgen). Prior to Ilypsa, he was VP, Chief Patent Counsel for Symyx (IPO in 1999). Mr. Stone received his J.D. from the University of Wisconsin Law School in 1995 and practiced as a Patent Attorney at Senniger, Powers, Leavitt & Roedel. He taught patent law, trade secrets law and licensing as an adjunct professor at the University of Missouri and Santa Clara University.
Follow Paul A. Stone:
About 5AM Ventures, IDEAYA Biosciences: IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality
Zack McNealy
CFO of Inception Sciences
Zack McNealy joined Ventus Therapeutics as CFO in 2019.Zack McNealy is the Vice President, Finance responsible for Versant’s domestic and international management company entities. Zack also works extensively with a number of Versant’s biotech portfolio companies on their international structuring and operational setup. Zack joined Versant after spending seven years at Biotie Therapies (formerly Synosia Therapeutics) where he was Vice President, Finance supporting the U.S. and Swiss operations of the company. Prior to Biotie, Zack spent ten years at Johnson & Johnson as Plant Controller, Finance Manager and Financial Analyst. Zack received an MBA from the Wharton School, University of Pennsylvania and a BS in finance and accounting from Miami University (Ohio).
Follow Zack McNealy:
About Inception Sciences, Ventus Therapeutics: Inception Sciences creates therapies with transformative potential to address diseases and disorders with significant unmet need.
Gordon Galloway
CFO of Vali Nanomedical
Gordon Galloway received his MBA from the UCLA Anderson School of Management and his BSBA from the UC Berkeley Haas School of Business. Of nine years working in finance, he spent three in banking and two at Stryker Corporation, a Fortune 500 manufacturer and technology leader in the medical device industry. At Stryker, he helped support the acquisition of two entrepreneurial startups in order to commercialize cutting-edge health care technology around the world. He has worked alongside Dr. Gray on a variety of projects for over a decade, and became Vali’s CFO in 2014.
Follow Gordon Galloway:
About Vali Nanomedical: Vali is a biotechnology company founded in 2013.